BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015; 7(10): 1412-1420 [PMID: 26052386 DOI: 10.4254/wjh.v7.i10.1412] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80. [PMID: 28130846 DOI: 10.1002/hep.29086] [Cited by in Crossref: 1730] [Cited by in F6Publishing: 1535] [Article Influence: 432.5] [Reference Citation Analysis]
2 Wu M, Lian B, Deng Y, Feng Z, Zhong C, Wu W, Huang Y, Wang L, Zu C, Zhao X. Resveratrol-loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles: Preparation, characterization, and targeting effect on liver tumors. J Biomater Appl 2017;32:191-205. [PMID: 28610486 DOI: 10.1177/0885328217713357] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
3 Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. Cancer Lett. 2016;370:78-84. [PMID: 26472630 DOI: 10.1016/j.canlet.2015.09.020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
4 Tawfik MM, Eissa N, Althobaiti F, Fayad E, Abu Almaaty AH. Nomad Jellyfish Rhopilema nomadica Venom Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Hepatocellular Carcinoma HepG2 Cells. Molecules 2021;26:5185. [PMID: 34500621 DOI: 10.3390/molecules26175185] [Reference Citation Analysis]
5 Wu C, Kan H, Hu M, Liu X, Boye A, Jiang Y, Wu J, Wang J, Yang X, Yang Y. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocarcinogenesis via modulating TGF-β/TβR and Imp7/8. Exp Ther Med 2018;16:1052-60. [PMID: 30112050 DOI: 10.3892/etm.2018.6292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Tharehalli U, Svinarenko M, Lechel A. Remodelling and Improvements in Organoid Technology to Study Liver Carcinogenesis in a Dish. Stem Cells Int 2019;2019:3831213. [PMID: 30915124 DOI: 10.1155/2019/3831213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Cai Y, Xu Y, Chan HF, Fang X, He C, Chen M. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy. Mol Pharm 2016;13:699-709. [PMID: 26808002 DOI: 10.1021/acs.molpharmaceut.5b00677] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 10.0] [Reference Citation Analysis]
8 Huang P, Zhang YH, Zheng XW, Liu YJ, Zhang H, Fang L, Zhang YW, Yang C, Islam K, Wang C, Naranmandura H. Phenylarsine oxide (PAO) induces apoptosis in HepG2 cells via ROS-mediated mitochondria and ER-stress dependent signaling pathways. Metallomics 2017;9:1756-64. [PMID: 28831476 DOI: 10.1039/c7mt00179g] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 4.6] [Reference Citation Analysis]
9 Caparelli ML, Roberts NJ, Braverman TS, Stevens RM, Broun ER, Allamaneni S. Metastatic recurrence to a solitary lymph node four years after hepatic lobectomy for primary hepatocellular carcinoma. World J Hepatol 2016; 8(23): 994-998 [PMID: 27621765 DOI: 10.4254/wjh.v8.i23.994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Hung AK, Guy J. Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review. World J Gastroenterol 2015; 21(42): 12197-12210 [PMID: 26576104 DOI: 10.3748/wjg.v21.i42.12197] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
11 Meng C, Shen X, Jiang W. Potential biomarkers of HCC based on gene expression and DNA methylation profiles. Oncol Lett 2018;16:3183-92. [PMID: 30127913 DOI: 10.3892/ol.2018.9020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
12 Yuan B, Bo W, Feng X, Hu Y, Zeng J. Overexpression of Rhophilin Rho GTPase-binding protein 2 promotes hepatocellular carcinoma. Oncol Lett 2020;20:382. [PMID: 33154780 DOI: 10.3892/ol.2020.12245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Long H, Guo X, Qiao S, Huang Q. Tumor LXR Expression is a Prognostic Marker for Patients with Hepatocellular Carcinoma. Pathol Oncol Res 2018;24:339-44. [PMID: 28508927 DOI: 10.1007/s12253-017-0249-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
14 Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Seminars in Diagnostic Pathology 2017;34:153-9. [DOI: 10.1053/j.semdp.2016.12.011] [Cited by in Crossref: 153] [Cited by in F6Publishing: 164] [Article Influence: 30.6] [Reference Citation Analysis]
15 Jiang Z, Shen L, Wang S, Wu S, Hu Y, Guo J, Fu L. Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma. Cancer Med 2019;8:7278-87. [PMID: 31595711 DOI: 10.1002/cam4.2584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zhang X, Zhou H, Jing W, Luo P, Qiu S, Liu X, Zhu M, Liang C, Yu M, Tu J. The Circular RNA hsa_circ_0001445 Regulates the Proliferation and Migration of Hepatocellular Carcinoma and May Serve as a Diagnostic Biomarker. Dis Markers. 2018;2018:3073467. [PMID: 29785229 DOI: 10.1155/2018/3073467] [Cited by in Crossref: 33] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
17 Luo P, Feng X, Jing W, Zhu M, Li N, Zhou H, Worley PF, Chai H, Tu J. Clinical and Diagnostic Significance of Homer1 in hepatitis B virus-induced Hepatocellular Carcinoma. J Cancer 2018;9:683-9. [PMID: 29556326 DOI: 10.7150/jca.22279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Ding W, Yang H, Gong S, Shi W, Xiao J, Gu J, Wang Y, He B. Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis. Oncol Lett 2017;13:3409-14. [PMID: 28521446 DOI: 10.3892/ol.2017.5913] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
19 Lock M, Meyers BM, Mujoomdar A. The addition of radiofrequency ablation for patients receiving sorafenib: new evidence for a new standard? Ann Transl Med 2021;9:3. [PMID: 33553296 DOI: 10.21037/atm-20-7474] [Reference Citation Analysis]
20 Jing X, Liang H, Cui X, Han C, Hao C, Huo K. Long noncoding RNA CCAT2 can predict metastasis and a poor prognosis: A meta-analysis. Clin Chim Acta 2017;468:159-65. [PMID: 28263738 DOI: 10.1016/j.cca.2017.03.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
21 Rahman M, Almalki WH, Alrobaian M, Iqbal J, Alghamdi S, Alharbi KS, Alruwaili NK, Hafeez A, Shaharyar A, Singh T, Waris M, Kumar V, Beg S. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opin Drug Deliv 2021;18:489-513. [PMID: 33225771 DOI: 10.1080/17425247.2021.1854223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X, Tu J. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res. 2020;26:599-603. [PMID: 30661224 DOI: 10.1007/s12253-019-00585-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
23 Chen M, Huang H, Pan Y, Li Z, Ouyang S, Ren C, Zhao Q. Preparation of layering-structured magnetic fluorescent liposomes and labeling of HepG2 cells. Biomed Mater Eng 2022. [PMID: 35180107 DOI: 10.3233/BME-228000] [Reference Citation Analysis]
24 Yi P, Huang M, Zhang M, Xu L, Xu M. Comparison of Transarterial Chemoembolization Combined with Radiofrequency Ablation Therapy versus Surgical Resection for Early Hepatocellular Carcinoma. The American Surgeon 2018;84:282-8. [DOI: 10.1177/000313481808400238] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
25 Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst 2020;32:5. [PMID: 32372179 DOI: 10.1186/s43046-020-0016-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
26 Kong FY, Wei X, Zhou K, Hu W, Kou YB, You HJ, Liu XM, Zheng KY, Tang RX. Bioinformatics Analysis Reveals Distinct Molecular Characteristics of Hepatitis B-Related Hepatocellular Carcinomas from Very Early to Advanced Barcelona Clinic Liver Cancer Stages. PLoS One 2016;11:e0158286. [PMID: 27454179 DOI: 10.1371/journal.pone.0158286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
27 Huang IT, Dhungel B, Shrestha R, Bridle KR, Crawford DHG, Jayachandran A, Steel JC. Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma. Expert Opin Investig Drugs 2019;28:7-18. [PMID: 30474444 DOI: 10.1080/13543784.2019.1551359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
28 Jiang Z, Wang S, Jin J, Ying S, Chen Z, Zhu D, Xiao B, Hu Y, Qian Y, Cai T, Fu L. The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases. J Clin Lab Anal 2020;34:e23200. [PMID: 31916309 DOI: 10.1002/jcla.23200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
29 Zhu M. Inhibitory effects of bortezomib in a subcutaneous tumor model of H22 mouse hepatocarcinoma cells. Pathol Res Pract 2019;215:152388. [PMID: 30914235 DOI: 10.1016/j.prp.2019.03.017] [Reference Citation Analysis]
30 Yi PS, Li JS. High expression of miR-21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma. Mol Clin Oncol 2018;8:733-9. [PMID: 29732156 DOI: 10.3892/mco.2018.1603] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
31 Nuciforo S, Fofana I, Matter MS, Blumer T, Calabrese D, Boldanova T, Piscuoglio S, Wieland S, Ringnalda F, Schwank G, Terracciano LM, Ng CKY, Heim MH. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Rep. 2018;24:1363-1376. [PMID: 30067989 DOI: 10.1016/j.celrep.2018.07.001] [Cited by in Crossref: 123] [Cited by in F6Publishing: 118] [Article Influence: 41.0] [Reference Citation Analysis]
32 Vassilaki N, Frakolaki E. Virus-host interactions under hypoxia. Microbes Infect 2017;19:193-203. [PMID: 27771294 DOI: 10.1016/j.micinf.2016.10.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
33 Wang X, Guo H, Liu W, Yang C, Yang L, Wang D, Wang X. Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell Lines. Med Sci Monit 2016;22:1291-6. [PMID: 27086779 DOI: 10.12659/msm.895853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Chen M, Zhou X, Chen R, Wang J, Ye RD, Wang Y, Wu C, Mahato RI. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today 2019;25:66-87. [DOI: 10.1016/j.mattod.2018.10.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
35 Chen BB, Hsu CY, Yu CW, Liang PC, Hsu C, Hsu CH, Cheng AL, Shih TT. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. Eur Radiol 2017;27:3069-79. [PMID: 27957638 DOI: 10.1007/s00330-016-4670-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
36 Chung M, Wang S, Lin C. Symptom Clusters and Impact of Fatigue and Sleep Disturbance on Symptom Experiences of Hepatoma Patients in Taiwan. Cancer Nurs 2017;40:403-11. [DOI: 10.1097/ncc.0000000000000417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]